Cytochrome P450 epoxygenase metabolite, 14,15-EET, protects against isoproterenol-induced cellular hypertrophy in H9c2 rat cell line

Vascular Pharmacology

Volumn 58, Issue 5-6, 2013, Pages 363-373

  Tse, Mandy M Y ^a   Aboutabl, Mona E ^b   Althurwi, Hassan N ^a   Elshenawy, Osama H ^a   Abdelhamid, Ghada ^a   El Kadi, Ayman O S ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b NATIONAL RESEARCH CENTRE   (Egypt)

Author keywords

14,15 EET; 20 HETE; Cardiac hypertrophy; Cytochrome P450s; H9c2 cells; Isoproterenol; Soluble epoxide hydrolase

Indexed keywords

14,15 EPOXY 5,8,11 ICOSATRIENOIC ACID; 20 HYDROXYICOSATETRAENOIC ACID; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 1B1; EPOXIDE HYDROLASE; ISOPRENALINE; MESSENGER RNA; PROTECTIVE AGENT;

ANIMAL CELL; ARTICLE; CELL LINE; CELL PROTECTION; CELL SURFACE; CONTROLLED STUDY; DRUG EFFECT; GENE EXPRESSION; HEART VENTRICLE HYPERTROPHY; NONHUMAN; PRIORITY JOURNAL; RAT; REAL TIME POLYMERASE CHAIN REACTION;

8,11,14-EICOSATRIENOIC ACID; ANIMALS; CARDIOMEGALY; CELL LINE; CYTOCHROME P-450 ENZYME SYSTEM; EPOXIDE HYDROLASES; GENE EXPRESSION REGULATION; HYDROXYEICOSATETRAENOIC ACIDS; ISOPROTERENOL; MYOCYTES, CARDIAC; RATS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; TIME FACTORS;

EID: 84877635687     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2013.02.004     Document Type: Article

References (53)

1. Abdel-Razzak Z., Garlatti M., Aggerbeck M., Barouki R. Determination of interleukin-4-responsive region in the human cytochrome P450 2E1 gene promoter. Biochem. Pharmacol. 2004, 68:1371-1381.
2. Aboutabl M.E., Zordoky B.N., El-Kadi A.O. 3-Methylcholanthrene and benzo(a)pyrene modulate cardiac cytochrome P450 gene expression and arachidonic acid metabolism in male Sprague Dawley rats. Br. J. Pharmacol. 2009, 158:1808-1819.
3. Aboutabl M.E., Zordoky B.N., Hammock B.D., El-Kadi A.O. Inhibition of soluble epoxide hydrolase confers cardioprotection and prevents cardiac cytochrome P450 induction by benzo(a)pyrene. J. Cardiovasc. Pharmacol. 2011, 57:273-281.
4. Ai D., Fu Y., Guo D., Tanaka H., Wang N., Tang C., Hammock B.D., Shyy J.Y., Zhu Y. Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:9018-9023.
5. Althurwi, H.N., Tse, M.M., Abdelhamid, G., Zordoky, B.N., Hammock, B.D., El-Kadi, A.O., in press. Soluble epoxide hydrolase inhibitor, tups, protects against isoproterenol-induced cardiac hypertrophy. British journal of pharmacology. http://dx.doi.org/10.1111/bph.12066.
6. Baldwin S.J., Bramhall J.L., Ashby C.A., Yue L., Murdock P.R., Hood S.R., Ayrton A.D., Clarke S.E. Cytochrome P450 gene induction in rats ex vivo assessed by quantitative real-time reverse transcriptase-polymerase chain reaction (TaqMan). Drug Metab. Dispos. 2006, 34:1063-1069.
7. Bleicher K.B., Pippert T.R., Glaab W.E., Skopek T.R., Sina J.F., Umbenhauer D.R. Use of real-time gene-specific polymerase chain reaction to measure RNA expression of three family members of rat cytochrome P450 4A. J. Biochem. Mol. Toxicol. 2001, 15:133-142.
8. Delozier T.C., Kissling G.E., Coulter S.J., Dai D., Foley J.F., Bradbury J.A., Murphy E., Steenbergen C., Zeldin D.C., Goldstein J.A. Detection of human CYP2C8, CYP2C9, and CYP2J2 in cardiovascular tissues. Drug Metab. Dispos. 2007, 35:682-688.
9. Elbekai R.H., El-Kadi A.O. Cytochrome P450 enzymes: central players in cardiovascular health and disease. Pharmacol. Ther. 2006, 112:564-587.
10. Elshenawy O.H., Anwar-Mohamed A., Abdelhamid G., El-Kadi A.O. Murine atrial HL-1 cell line is a reliable model to study drug metabolizing enzymes in the heart. Vascul. Pharmacol. 2013, 58:326-333.
11. Gross G.J., Gauthier K.M., Moore J., Falck J.R., Hammock B.D., Campbell W.B., Nithipatikom K. Effects of the selective EET antagonist, 14,15-EEZE, on cardioprotection produced by exogenous or endogenous EETs in the canine heart. Am. J. Physiol. Heart Circ. Physiol. 2008, 294:H2838-H2844.
12. Grygielko E.T., Martin W.M., Tweed C., Thornton P., Harling J., Brooks D.P., Laping N.J. Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-beta type I receptor kinase in puromycin-induced nephritis. J. Pharmacol. Exp. Ther. 2005, 313:943-951.
13. Guengerich F.P. Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem. Res. Toxicol. 2001, 14:611-650.
14. Hirasawa F., Kawagoe M., Arany S., Koizumi Y., Ueno Y., Sugiyama T. Styrene monomer primarily induces CYP2B1 mRNA in rat liver. Xenobiotica 2005, 35:1089-1099.
15. Imig J.D., Zhao X., Capdevila J.H., Morisseau C., Hammock B.D. Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension 2002, 39:690-694.
16. Kalsotra A., Anakk S., Boehme C.L., Strobel H.W. Sexual dimorphism and tissue specificity in the expression of CYP4F forms in Sprague Dawley rats. Drug Metab. Dispos. 2002, 30:1022-1028.
17. Korashy H.M., El-Kadi A.O. Differential effects of mercury, lead and copper on the constitutive and inducible expression of aryl hydrocarbon receptor (AHR)-regulated genes in cultured hepatoma Hepa 1c1c7 cells. Toxicology 2004, 201:153-172.
18. Kuwahara F., Kai H., Tokuda K., Kai M., Takeshita A., Egashira K., Imaizumi T. Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation 2002, 106:130-135.
19. Lee S.J., Landon C.S., Nazian S.J., Dietz J.R. Cytochrome P-450 metabolites in endothelin-stimulated cardiac hormone secretion. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2004, 286:R888-R893.
20. Li N., Liu J.Y., Timofeyev V., Qiu H., Hwang S.H., Tuteja D., Lu L., Yang J., Mochida H., Low R., Hammock B.D., Chiamvimonvat N. Beneficial effects of soluble epoxide hydrolase inhibitors in myocardial infarction model: insight gained using metabolomic approaches. J. Mol. Cell. Cardiol. 2009, 47:835-845.
21. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 2001, 25:402-408.
22. Michaud V., Frappier M., Dumas M.C., Turgeon J. Metabolic activity and mRNA levels of human cardiac CYP450s involved in drug metabolism. PLoS One 2010, 5:e15666.
23. Miyata N., Roman R.J. Role of 20-hydroxyeicosatetraenoic acid (20-HETE) in vascular system. J. Smooth Muscle Res. 2005, 41:175-193.
24. Monti J., Fischer J., Paskas S., Heinig M., Schulz H., Gosele C., Heuser A., Fischer R., Schmidt C., Schirdewan A., Gross V., Hummel O., Maatz H., Patone G., Saar K., Vingron M., Weldon S.M., Lindpaintner K., Hammock B.D., Rohde K., Dietz R., Cook S.A., Schunck W.H., Luft F.C., Hubner N. Soluble epoxide hydrolase is a susceptibility factor for heart failure in a rat model of human disease. Nat. Genet. 2008, 40:529-537.
25. Motoki A., Merkel M.J., Packwood W.H., Cao Z., Liu L., Iliff J., Alkayed N.J., Van Winkle D.M. Soluble epoxide hydrolase inhibition and gene deletion are protective against myocardial ischemia-reperfusion injury in vivo. Am. J. Physiol. Heart Circ. Physiol. 2008, 295:H2128-H2134.
26. Ng V.Y., Huang Y., Reddy L.M., Falck J.R., Lin E.T., Kroetz D.L. Cytochrome P450 eicosanoids are activators of peroxisome proliferator-activated receptor alpha. Drug Metab. Dispos. 2007, 35:1126-1134.
27. Pang W., Li N., Ai D., Niu X.L., Guan Y.F., Zhu Y. Activation of peroxisome proliferator-activated receptor-gamma downregulates soluble epoxide hydrolase in cardiomyocytes. Clin. Exp. Pharmacol. Physiol. 2011, 38:358-364.
28. Pat Kunert M., Drenjancevic I. 20-Hydroxyeicosatetraenoic acid, endothelial dysfunction and hypertension. Med. Glas. Ljek komore Zenicko-doboj kantona 2011, 8:170-180.
29. Peng H.M., Coon M.J. Promoter function and the role of cytokines in the transcriptional regulation of rabbit CYP2E1 and CYP2E2. Arch. Biochem. Biophys. 2000, 382:129-137.
30. Rollin R., Mediero A., Fernandez-Cruz A., Fernandez-Durango R. Downregulation of the atrial natriuretic peptide/natriuretic peptide receptor-C system in the early stages of diabetic retinopathy in the rat. Mol. Vis. 2005, 11:216-224.
31. Roman R.J. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol. Rev. 2002, 82:131-185.
32. Rushmore T.H., Kong A.N. Pharmacogenomics, regulation and signaling pathways of phase I and II drug metabolizing enzymes. Curr. Drug Metab. 2002, 3:481-490.
33. Scarborough P.E., Ma J., Qu W., Zeldin D.C. P450 subfamily CYP2J and their role in the bioactivation of arachidonic acid in extrahepatic tissues. Drug Metab. Rev. 1999, 31:205-234.
34. Schmittgen T.D., Livak K.J. Analyzing real-time PCR data by the comparative C(T) method. Nat. Protoc. 2008, 3:1101-1108.
35. Sellers K.W., Sun C., Diez-Freire C., Waki H., Morisseau C., Falck J.R., Hammock B.D., Paton J.F., Raizada M.K. Novel mechanism of brain soluble epoxide hydrolase-mediated blood pressure regulation in the spontaneously hypertensive rat. FASEB J. 2005, 19:626-628.
36. + channels and p42/p44 MAPK pathway. Circ. Res. 2004, 95:506-514.
37. Seubert J.M., Sinal C.J., Graves J., DeGraff L.M., Bradbury J.A., Lee C.R., Goralski K., Carey M.A., Luria A., Newman J.W., Hammock B.D., Falck J.R., Roberts H., Rockman H.A., Murphy E., Zeldin D.C. Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function. Circ. Res. 2006, 99:442-450.
38. Soppa G.K., Lee J., Stagg M.A., Felkin L.E., Barton P.J., Siedlecka U., Youssef S., Yacoub M.H., Terracciano C.M. Role and possible mechanisms of clenbuterol in enhancing reverse remodelling during mechanical unloading in murine heart failure. Cardiovasc. Res. 2008, 77:695-706.
39. Spector A.A., Fang X., Snyder G.D., Weintraub N.L. Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function. Prog. Lipid Res. 2004, 43:55-90.
40. Tan F.L., Moravec C.S., Li J., Apperson-Hansen C., McCarthy P.M., Young J.B., Bond M. The gene expression fingerprint of human heart failure. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:11387-11392.
41. Thum T., Borlak J. Gene expression in distinct regions of the heart. Lancet 2000, 355:979-983.
42. Thum T., Borlak J. Cytochrome P450 mono-oxygenase gene expression and protein activity in cultures of adult cardiomyocytes of the rat. Br. J. Pharmacol. 2000, 130:1745-1752.
43. Thum T., Borlak J. Testosterone, cytochrome P450, and cardiac hypertrophy. FASEB J. 2002, 16:1537-1549.
44. Wu S., Moomaw C.R., Tomer K.B., Falck J.R., Zeldin D.C. Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. J. Biol. Chem. 1996, 271:3460-3468.
45. Wu S., Chen W., Murphy E., Gabel S., Tomer K.B., Foley J., Steenbergen C., Falck J.R., Moomaw C.R., Zeldin D.C. Molecular cloning, expression, and functional significance of a cytochrome P450 highly expressed in rat heart myocytes. J. Biol. Chem. 1997, 272:12551-12559.
46. Xu C., Li C.Y., Kong A.N. Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch. Pharm. Res. 2005, 28:249-268.
47. Xu D., Li N., He Y., Timofeyev V., Lu L., Tsai H.J., Kim I.H., Tuteja D., Mateo R.K., Singapuri A., Davis B.B., Low R., Hammock B.D., Chiamvimonvat N. Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:18733-18738.
48. Zeldin D.C., Kobayashi J., Falck J.R., Winder B.S., Hammock B.D., Snapper J.R., Capdevila J.H. Regio- and enantiofacial selectivity of epoxyeicosatrienoic acid hydration by cytosolic epoxide hydrolase. J. Biol. Chem. 1993, 268:6402-6407.
49. Zeldin D.C., DuBois R.N., Falck J.R., Capdevila J.H. Molecular cloning, expression and characterization of an endogenous human cytochrome P450 arachidonic acid epoxygenase isoform. Arch. Biochem. Biophys. 1995, 322:76-86.
50. Zordoky B.N., El-Kadi A.O. H9c2 cell line is a valuable in vitro model to study the drug metabolizing enzymes in the heart. J. Pharmacol. Toxicol. Methods 2007, 56:317-322.
51. Zordoky B.N., El-Kadi A.O. 2,3,7,8-Tetrachlorodibenzo-p-dioxin and beta-naphthoflavone induce cellular hypertrophy in H9c2 cells by an aryl hydrocarbon receptor-dependant mechanism. Toxicol. In Vitro 2010, 24:863-871.
52. Zordoky B.N., Aboutabl M.E., El-Kadi A.O. Modulation of cytochrome P450 gene expression and arachidonic acid metabolism during isoproterenol-induced cardiac hypertrophy in rats. Drug Metab. Dispos. 2008, 36:2277-2286.
53. Zordoky B.N., Anwar-Mohamed A., Aboutabl M.E., El-Kadi A.O. Acute doxorubicin toxicity differentially alters cytochrome P450 expression and arachidonic acid metabolism in rat kidney and liver. Drug Metab. Dispos. 2011, 39:1440-1450.